Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Pelthos Therapeutics Inc

PTHS ✗ NOT COMPLIANT ☆ Track — members

NYSE American · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$27.20

▲ +2.18%

Market Cap $104.13M · Vol 3.51K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$104.13M

Micro Cap

Div Yield

N/A

EPS Growth

+51.72%

YoY

RSI (14)

43.66

Momentum

Beta

N/A

vs Market

52W High

$37.42

27.31% below

52W Low

$18.19

49.53% above

Volume

3.51K

Avg 4.73K

P/B

2.58

Price-to-book

ROE

N/A

Return on equity

Free Float

43.87%

Public shares

Shariah Compliance8 STANDARDS

✗ Pelthos Therapeutics Inc (PTHS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PTHS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.17%

+4.94%

+2.03%

+18.26%

YTD

-12.26%

+20.41%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$16.80M
Net Income	$-43,319,000.00
Revenue Growth (YoY)	N/A
Gross Margin	66.99%
Operating Margin	-193.09%
Net Profit Margin	-257.93%
ROE	N/A
ROA · ROIC	-76.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	3.47
P/B	2.58
P/FCF	N/A
EPS Growth	+51.72%
Outstanding Shares	3.83M

Technical Indicators

50-Day SMA	$27.33
200-Day SMA	$25.79
RSI (14)	43.66
Beta	N/A
52-Week High	$37.42
52-Week Low	$18.19

Volume Today	3.51K
Avg Daily Volume (30D)	4.73K
Relative Volume	0.74x
Volatility (10D)	53.63
Volatility (30D)	70.84
Free Float	43.87%

Analyst Consensus

BUY

Current Price $27.20

Mean Target $53.14

52W Low$18.19 52W High$37.42

Current

Target

$18.19 $37.42

Current Analyst target

+95.38% upside potential · 7 analysts

Identifiers

ExchangeNYSE American

FIGIN/A

ISINUS1711262048

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -1.06% JNJ Johnson & Johnson +0.04% ABBV Abbvie Inc +0.48% NVS Novartis AG +1.24% NOVN.S Novartis AG +1.25%

Company Profile

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.